Comparison of the effects of Omapatrilat and Lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure

American Journal of Cardiology

Volumn 90, Issue 5, 2002, Pages 496-500

  Sheth, Tej ^a   Parker, Tom ^a   Block, Alan ^c   Hall, Christian ^d   Adam, Albert ^e   Pfeffer, Mark A ^f   Stewart, Duncan J ^a,b   Qian, Chunlin ^c   Rouleau, Jean L ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; CATECHOLAMINE; CYTOKINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LISINOPRIL; NEUROHORMONE; NITRATE; OMAPATRILAT; VASOPEPTIDASE INHIBITOR;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENCY; FEMALE; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CHRONIC DISEASE; CYTOKINES; DOUBLE-BLIND METHOD; ENDOTHELIN-1; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; LISINOPRIL; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEUROTRANSMITTER AGENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PYRIDINES; STROKE VOLUME; THIAZEPINES; TREATMENT OUTCOME;

EID: 0036711320     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02521-3     Document Type: Article

References (18)

1. Corti R., Burnett J.C., Rouleau J.L., Ruschitzka F., Luscher T.F. Vasopeptidase inhibitors a new therapeutic concept in cardiovascular disease . Circulation. 104:2001;1856-1862.
2. Blais C. Jr, Marceau F., Rouleau J.L., Adam A. The kallikrein-kininogen-kinin system lessons from the quantification of endogenous kinins . Peptides. 21:2000;1903-1940.
3. Rouleau J., Pfeffer M.A., Stewart D.J., Isaac D., Sestier F., Kerut E.K., Porter C.B., Proulx G., Qian C., Block A.J. Comparison of vasopeptidase inhibitor, omapatrilat and lisinopril on exercise tolerance and morbidity in patients with heart failure IMPRESS randomised trial . Lancet. 356:2000;615-620.
4. Rouleau J.L., de Champlain J., Klein M., Bichet D., Moye L., Packer M., Dagenais G.R., Sussex B., Arnold J.M., Sestier F., SAVE Investigators . Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol. 22:1993;390-398.
5. Sia Y.T., Parker T.G., Liu P., Tsoporis J.N., Adam A., Rouleau J.L. Improved post-myocardial infarction with probucol in rats effects of left ventricular function, morphology, cardiac oxidative stress and cytokine expression . J Am Coll Cardiol. 39:2002;148-156.
6. Benedict C.R., Shelton B., Johnstone D.E., Francis G., Greenberg B., Konstam M., Probstfield J.L., Yusuf S. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation. 94:1996;690-697.
7. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med. 339:1998;321-328.
8. Wilkins M.R., Redondo J., Brown L.A. The natriuretic-peptide family. Lancet. 349:1997;1307-1310.
9. Benedict C.R., Johnstone D.E., Weiner D.H., Bourassa M.G., Bittner V., Kay R., Kirlin P., Greenberg B., Kohn R.M., Nicklas J.M., SOLVD Investigators . Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction a report from the registry of SOLVD . J Am Coll Cardiol. 23:1994;1410-1420.
10. Hall C., Rouleau J.L., Moye L., de Champlain J., Bichet D., Klein M., Sussex B., Packer M., Rouleau J., Arnold M.O., SAVE Investigators . N-Terminal proatrial natriuretic factor an independent predictor of long-term prognosis after myocardial infarction . Circulation. 89:1994;1934-1942.
11. Omland T., Aakvaag A., Bonarjee V.V.S., Caidahl K., Lie R.T., Nilsen D.W., Sundsfjord J.A., Dickstein K. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation. 93:1996;1963-1969.
12. Maeda K., Tsutamoto T., Wada A., Hisanaga T., Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker for high left ventricular end-diastolic pressure in patients with symptomatic left-ventricular dysfunction. Am Heart J. 135:1998;825-832.
13. Richards A.M., Doughty R., Nicholls G., MacMahon S., Sharpe N., Murphy J., Espiner E.A., Frampton C., Yandle T., Australia-New Zealand Heart Failure Group . Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction . J Am Coll Cardiol. 37:2001;1781-1787.
14. Rouleau J.L., Packer M., Moye L., de Champlain J., Bichet D., Klein M., Rouleau J.R., Sussex B., Arnold J.M., Sestier F., SAVE Investigators . Prognostic value of neurohumoral activation in patients with an acute myocardial infarction effect of captopril . J Am Coll Cardiol. 24:1994;583-591.
15. Vantrimpont P., Rouleau J.L., Ciampi A., Harel F., de Champlain J., Bichet D., Moye L.A., Pfeffer M. Two-year time course and significance of neurohumoral activation in the SAVE study. Eur Heart J. 19:1998;1552-1563.
16. Kazanegra R., Cheng V., Garcia A., Krishnaswamy P., Gardetto N., Clopton P., Maisel A. A rapid test for B-type natriuretic peptide correlated with falling filling pressures in patients treated for decompensated heart failure. J Card Failure. 7:2001;21-29.
17. Wei C.M., Lerman A., Rodeheffer R.J., McGregor C.G.A., Brandt R.R., Wright S., Heublein D.M., Kao P.C., Edwards E.D., Burnett J.C. Endothelin in human congestive heart failure. Circulation. 89:1994;1580-1589.
18. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., Mann D.L. Cytokines and cytokine receptors in advanced heart failure an analysis of the cytokine database from the Vesnarinone Trial (VEST) . Circulation. 103:2001;2055-2059.